Connect with us

Health Care

CardieX (ASX:CDX) – Craig Cooper



The CEO Mindset - Craig Cooper is Chief Executive Officer of CardieX (ASX:CDX)

Craig Cooper is Chief Executive Officer of CardieX (ASX:CDX), an ASX listed public company with operations in medical technologies, wearable devices, and telehealth solutions. We provide digital and device-based solutions for large-scale population health disorders with significant market scale. Our fundamental mission is to develop a significant and valuable healthcare ecosystem of complementary and strategic products and services in order to provide smarter tools to help identify, diagnose, and treat patients with confidence.

What’s your journey in becoming a CEO?
I’ve founded or co-founded multiple companies in the past in different sectors, most notably in energy (NRG Asia), and telecommunications (Boost Mobile USA). I’ve also been an active investor in the digital media and health-tech space through my venture capital funds which have raised over a billion US dollars. My path is a culmination of both my operating and investment experience over the last 25 years. Through my venture investments I’ve also been lucky to have an inside view of hundreds of companies (and their CEOs) and the tools and processes that have led those companies to success (or failure) and it’s that experience that underlies my own executive and management style.

In today’s world everything moves so fast so there’s no real time for “a journey in becoming a CEO”. Most CEOs in tech, for example, are the original founders, and for most of them it’s their first company at an age that 30 years ago you’d never consider appropriate for a CEO of a multibillion-dollar company. Steve Jobs was 21 when he founded Apple. Bill Gates was 16 when he founded Microsoft. Mark Zuckerberg was 19 when he started Facebook. There is no learning curve in today’s world – you sink or swim.

Tell us a bit about your business and how you are commercializing?
We make devices and solutions for diagnosing and managing the #1 killer in the world today – cardiovascular disease. Our “XCEL”, a unique device that measures central blood pressure is the only FDA cleared device for measuring arterial stiffness and inflammation non-invasively in adults. Our technology is also the world leader in measuring central blood pressure waveforms which, in layman’s terms, allows physicians to get a complete picture of the state of a patient’s arterial health.

Our traditional focus has been on sales to pharmaceutical companies, research institutions, and specialist clinicians such as Nephrologists and Cardiologists. Our future product strategy however, is focused on taking our technology into large scale consumer markets through home and clinician devices, wearables and smart watches, and software solutions that allow clinicians to better manage their patients’ health.

Our solutions are particularly relevant in the current market given that COVID-19 is being seen more and more as a cardiovascular disease rooted in arterial inflammation. Providing consumers and clinicians with better ways to detect the COVID-19 disease is a core focus of our product development efforts.

How are you managing with the current COVID-19 pandemic on both business and personal front?
When COVID-19 hit we saw some initial slowdown with some of our process and manufacturing partnerships which was to be expected – but it’s now back to “business as usual” for us. We’re lucky that, being a tech firm, we can all operate remotely at full capacity and, in fact, my team seems to be working harder and more efficiently than ever before in this virtual environment. I’ve set up my company office as a kind of Zoom command center with lighting and proper cameras as well as other features to enable better inter-company communications. I’m on video calls a lot with investors and other stakeholders so it’s important to look professional. I told my team from the start, “this is not a holiday so don’t turn up on Zoom in your pyjamas!”. Although it’s hard to think that I won’t have my team around a table in person for the foreseeable future, it is what it is. The top priority for us is to keep everyone healthy so we can all get back to some level of normalcy ASAP.

For me personally, it’s definitely been tough. Everyone is struggling in their own way (well, except maybe for the founders of Netflix, Amazon, and Zoom!). I live in Orange County, California which is currently experiencing some of the highest infection and death rates in the USA. I’m also physically separated from my daughters who live in Australia so that hasn’t been easy. I stay sane by focusing on my exercise, nutrition, and maintaining my social connections as best as I can.

What’s the most exciting thing about running your business?
The thing that gets me jumping out of bed every morning is the knowledge that we are making a massive positive impact on global health with our technology and solutions. We’re disrupting an industry that hasn’t seen any real innovation in over a hundred years and showing that there’s a better way to identify, diagnose, treat, and manage the #1 killer of humans. There couldn’t be a better mission than that.

How do you measure success?
Am I making a positive impact on humanity? It’s that simple to me.

What do you think is the most important quality of being a CEO of a listed company?
You need to be a ringmaster of multiple stakeholders. Not only do you have to run a business, which is hard enough in itself; you also need to run an entirely separate business of managing the public capital markets. When you’re private (unlisted) you’re free to build a business without the glare and oversight of your shareholders on a daily basis, which is not a luxury you have as a public company. The goal of so many companies in Australia is to list on the ASX but I would question whether 80% of them should even be there – especially if you’re a small-cap growth technology company. Companies in our sector, for example, are valued at 10-20x in the private sector in the USA with similar revenues and comparable market opportunities. I’m biased of course but I think we are the most undervalued company on the ASX today.

What is your favorite book?
I’m a voracious reader and always have a backlog of books sitting on my Kindle. At the moment I’m obsessed with The Atlantis Gene trilogy which I’m just finishing up. It’s a multi-layered time traveling exploration of the origin of humanity – set against the backdrop of a fight to control the universe and create a single species – and it spans millions of years of evolution across multiple galaxies. It’s not easy reading but it covers so many themes that I’m passionately interested in, particularly the origin of species and bio-genesis. It’s also relevant at the moment because the story on Earth revolves around a global plague that is pitting different political factions against each-other.

What message do you want to send to our readership in Asia?
We’re actively looking for partnerships and collaboration opportunities in Asia. We have a corporate office and team in Shanghai that curates our licensing and other partnerships in that country and we’re actively looking to expand those partnerships beyond the Chinese market. We currently have a (yet to be announced) manufacturing partnership in China, as well as our Joint Venture with Mobvoi, Google’s in-country partner in China for the Wear OS operating system. The Oscar 2 (24-hour blood pressure monitor with our SphygmoCor technology inside) is sold in China (NMPA approved) and we’re looking for distribution partnerships for our new range of blood pressure wearables and home devices which will be FDA and NMPA cleared in 2021.

We are also looking for strategic partnerships that share our vision of reducing the impact of cardiovascular and arterial disease and lessening the rates of hypertension related disorders.

How can people connect with you?
IR Email:

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises –

CEO Craig Cooper on one of his laboratories visit

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health Care

Q&A With StockPal – Exopharm (ASX:EX1)



Q&A with StockPal - Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1)

Watch Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1), as he explains about the Exopharm’s latest developments and potential target markets.

0:00 – Intro

0:10 – What is your business about?

1:20 – Tell us about your product developments and pipeline?

3:01 – What is the size of your potential target markets?

4:16 – What is EX1’s competitive advantage?

5:30 – How did your company cope during the COVID-19 pandemic?

6:28 – How are you currently engaging with your investors?

Visit Exopharm’s website:

Email if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises –

Continue Reading

Health Care

The ONE way to deliver digital healthcare solutions



The ONE way to deliver digital healthcare solutions

The focus on digital health has become a global trend.

The long-term benefits of technological adaptation in this space will most likely be a reduction in unnecessary use of health services, alleviating the burden on undermanned or under resourced health providers, reduced costs and better, more efficient patient care.

Global Market Insights estimates the global digital health market  to be worth US$639B in 2026 and outlines several growth drivers, including the rising adoption of smart devices, improving healthcare IT infrastructure, favourable government regulations and initiatives, and rising demand for remote patient monitoring services.

The factors have been at the forefront of OneView Healthcare plc’s (ASX:ONE) thinking.

ONE is a health tech company that provides hospital patients a “virtual care and digital control centre” at their bedside to deliver the best possible patient experience during their stay.

Its software (SaaS) platform is sold as a yearly license fee per hospital bed, with the pandemic accelerating the uptake of this platform.

In fact its control centre, is currently used in 9,259 hospital beds around the world, including three of the top 20 hospitals in the USA.

ONE’s tech provides patients with a single touch screen at their hospital bed where patients can:

  • Have virtual consultations with relevant medical specialists – local and from around the world
  • Control all aspects of their room (bed, lighting, temperature),
  • Order food, watch movies, get a nurse’s attention (think airline business class screens)
  • Interact with tailored rehab, education and training videos for YOUR health situation, and;
  • Monitor your health outcomes – Doctors and nurses have better info on you.

A single point of care

ONE was founded as a software and solutions business operations in 2008, with the objective of enabling healthcare organisations to make use of technology to drive cost efficiencies, improvements in clinical outcomes and enhanced patient satisfaction.

The idea was to create an experience leading to overall excellence in healthcare economics and quality of care.

For patients, ONE offers digital tools to help control their experience with virtual care at the bedside. ONE delivers a SaaS experience that transcends current in-room technology.

Oneview at the patient’s bedside

For the care team, optimisation of patient flow and patient experience becomes more personalised and engaging.

Effectively, Oneview offers a secure, flexible and scalable platform where the digital infrastructure for content, apps and services is at one point of care.

Uptake proves uplifting for ONE

Given the uptake and interest in the ONE solution, the company has delivered on many key metrics.

Highlights include:

  • Expanded global footprint – live beds up 9% YOY to 9,259
  • Recurring revenue up 13% to €5.1M, reflecting expanded user base despite short-term impact to recurring revenue growth as COVID-19 delayed scheduled deployments
  • Improvement across key operational performance metrics, delivering reduced cash burn and cost
  • Significant progress on product development–central to growth strategy including investment in next generation platform
  • Process improvements and engineering offshoring
  • Material improvements in productivity
  • Enabling rapid delivery of the first cloud solution, Cloud for COVID-19.

Further to this recurring revenue is up by 13% to €5.1m (A$8.0m) due to expansion of live beds.

Covid-19 did have one negative impact for ONE: it prevented access to hospital sites, delaying installation and the go-live increase rate.

This is is expected to normalise in 2021.

Overall, the company has delivered higher gross margins. Gross profit margins improved 67% (up from 60% in FY19) due to changing revenue mix towards higher margin software recurring revenue.

The company had also enjoyed improved operational performance due to a  focus on cost control. It has reduced operating expenses by 44% and improved operating EBITDA by 60% to a loss of €6.2m (A$9.7m).

There is also reduced cash burn and the cash balance of €6.8m (A$10.6m) reflects the €4.8m (A$8.7m before costs) capital raise conducted in Nov/Dec 2020 and the significant reduction in operating cash burn.

Interestingly, ONE currently has $7.85M in Annual Recurring Revenue (ARR) and is projecting 45% growth this year. However, this does not factor in any future revenue from Samsung.

Samsung sees the value of ONE’s technology

ONE signed a Distribution Agreement with Samsung SDS America, Inc., the enterprise IT solutions provider of Samsung, to offer a bundled solution for bedside digital services for patients in the United States.

The agreement went live in February this year.

Samsung SDSA will bundle Samsung tablets with Oneview Cloud Start –the first tier in Oneview’s new product suite.

The bundle will be distributed to healthcare-enterprise focused enterprise resellers.

“Our move to the cloud accelerates speed to market and opens new possibilities for distribution, making it faster, easier and lower-cost for end-customers to benefit from the digital platform at the bedside,” ONE CEO James Fitter said.

“Never has this need been so apparent. Our partnership with Samsung provides a unique opportunity to address new virtual models of care and provide the solution for Samsung SDSA to enhance the value proposition for their reseller network.”

The agreement is designed to continue the improvement in US healthcare, in particular patient care.

Mingu Lee, Chief Business Officer and Senior Vice President, Samsung SDS America, said “Our distribution partnership with Oneview Healthcare enables us to deliver a more cost-effective and impactful solution, allowing caregivers to work efficiently while providing a connected experience for patients.”

The agreement not only opens up further revenue streams for ONE, but also provides customers with an upgrade path to ONE’s Cloud Enterprise tier with additional features.

Strategic partnerships including its Samsung agreement and an agreement with Microsoft, Cloudbreak and Caregility, with whom it entered a partnership to enable customers to scale inpatient telehealth across the enterprise as the COVID-19 pandemic continued to ravage Dublin, Ireland, continue to define ONE’s go to market strategy especially in the US where there are 6000 hospitals.

ONE’s full SaaS platform is anticipated by the end of Q1 2021.

ONE is trading at 21.5 cents.

Continue Reading

Health Care

Q&A With StockPal – Neuren Pharmaceuticals (ASX:NEU)



Q&A with StockPal - Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX:NEU)

Watch Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX:NEU), speaking about Neuren’s area of drug focus and the latest updates on the Trofinetide development.

0:11 – Firstly, can you tell us about the area of drug development that Neuren is focused on?

0:58 – The syndromes you are treating occur in children. Could you tell us more about how they are affected by these diseases?

1:48 – You have US partner ACADIA for Trofinetide – could you tell us the arrangement in this deal?

3:08 – Can you tell us about the orphan drug status of your drugs and what are the benefits of this designation?

4:34 – Results from the Phase 3 study of Trofinetide in Rett Syndrome are expected in the second half of this year. How is Neuren looking to capitalize on these results?

5:14 – Neuren’s second drug NNZ-2591 is commencing a Phase 2 trials this year. How will the company fund such a broad clinical program?

5:47 – Lastly, what are your top priorities for the year ahead and what key milestones do investors have to look forward to?

Visit Neuren’s website to learn more about their story:

Email if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises –

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Recent Posts